What Beijing Strong Biotechnologies does

Beijing Strong Biotechnologies (BSBE; 北京九强生物技术股份有限公司) is a Chinese in vitro diagnostics (IVD) manufacturer founded in 2001 and headquartered in Beijing, listed on the Shenzhen Stock Exchange GEM under stock code 300406. The company is affiliated with Sinopharm Group following a 2020 strategic investment by Sinopharm Investment. BSBE operates six integrated detection platforms — biochemistry (under the proprietary Kingsle/金斯尔 brand), coagulation, chemiluminescence immunoassay (Gi-series), blood typing (micro-column gel cards), pathology (via the acquired Maixin/迈新 brand), and liquid biopsy CTC — supported by proprietary instruments (MDC and Coatron coagulation analyzers, Gi-series chemiluminescence analyzers, Titan/Titan S pathology stainers) and a comprehensive reagent menu spanning liver, renal, lipid, cardiac, diabetes, tumor marker, and specialty coagulation panels.

BSBE's technology stack spans latex-enhanced immunoturbidimetry, chemiluminescence, chromogenic substrate, coagulation, and micro-column gel methods, with manufacturing anchored at the Huairou production base in Beijing (operational since 2006). The reference laboratory is one of only 16 globally listed in the JCTLM database and holds CNAS accreditation, NMPA medical device registrations, CE IVDR certification, and National Enterprise Technology Center designation, validating reference measurement capability at international first-tier level. BSBE has accumulated multiple utility and invention patents covering instrument components, sample handling, and chemical formulations for immunoassays.

The company pursues a hybrid go-to-market combining a direct sales force for tier-3 hospital laboratories and key accounts, a domestic distributor network for grassroots and mid-tier institutions, and strategic international partnerships with Abbott, Roche Diagnostics, Beckman Coulter, and Diasorin (signed December 2025) for overseas market access. Pricing is set through hospital tenders and regional procurement rather than public disclosure. Customer segments are hospital laboratories, medical institution inspection departments, and IVD distributors across China, with expanding overseas reach into Europe, the Middle East, and Southeast Asia. The 2024 launch of the GTA6000 intelligent laboratory solution positions BSBE as a one-stop integrated workflow provider across its six detection platforms.

Name

Beijing Strong Biotechnologies

Legal name

Beijing Strong Biotechnologies, Inc. (北京九强生物技术股份有限公司)

Website

https://bsbe.com.cn

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Beijing Strong Biotechnologies is a Sinopharm-affiliated Chinese IVD manufacturer offering six integrated detection platforms — biochemistry, coagulation, chemiluminescence, blood typing, pathology, and CTC liquid biopsy — to hospital laboratories across China and select international markets.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industries

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• In-vitro diagnostics
• Clinical chemistry reagents
• Automated coagulation analyzers
• Chemiluminescence immunoassays
• Blood typing reagents

Headquarters

HQ city

Haidian

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. 体外诊断试剂及仪器销售: 九强生物主要通过销售自有品牌的体外诊断试剂和仪器设备获得收入。产品涵盖生化试剂、凝血试剂、化学发光试剂、血型检测产品和病理检测产品等六大检测系统，同时提供配套的全自动生化分析仪、凝血分析仪、化学发光免疫分析仪和血型分析仪等仪器设备。

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Beijing Strong Biotechnologies (BSBE) develops, manufactures, and sells in-vitro diagnostic (IVD) reagents and automated analyzers across six detection platforms: clinical biochemistry, blood coagulation, chemiluminescence immunoassay, blood typing, pathology, and liquid biopsy CTC. The company markets its products under proprietary brands such as Jinsier (Kingsle) for biochemistry reagents and Maixin for pathology, supplying hospital laboratories and medical institutions in China and selected overseas markets.

Product overview

Beijing Strong Biotechnologies (BSBE) is a Sinopharm Group-affiliated in-vitro diagnostics (IVD) company listed on Shenzhen GEM (stock: 300406). The company operates as a multi-platform diagnostics provider offering six integrated detection systems: biochemistry reagents (金斯尔 brand), coagulation reagents and analyzers (MDC series), chemiluminescence immunoassay (Gi series: Gi9000/Gi2000/Gi1600), blood grouping cards, pathology (via the acquired Maixin brand), and liquid biopsy CTC. BSBE's product portfolio spans reagents for clinical chemistry testing across liver, renal, lipid, cardiac, diabetes, tumor marker, inflammation, and therapeutic drug monitoring panels; coagulation testing reagents and automated analyzers (MDC3500, MDC7500, MDC7600, Coatron series, Gx 3000); micro-column gel blood grouping cards; automated chemiluminescence immunoassay systems; automated pathology staining equipment (Titan, Titan S) and primary antibodies; and the intelligent laboratory solution (GTA6000). The portfolio is organized around six major detection platforms that can be integrated into an intelligent laboratory ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

• 金斯尔 (Kingsle): Proprietary brand of biochemical reagents launched in 2002

Products and services

• Biochemistry Reagent Portfolio (Jinsier Brand) Comprehensive line of biochemistry reagents for quantitative in-vitro determination of clinical biomarkers (liver function, renal function, lipid profiles, cardiac markers, diabetes, special proteins, tumor markers, pancreas, inorganic ions, inflammation, therapeutic drug monitoring), used on automated biochemistry analyzers in hospital clinical laboratories.
• Coagulation Reagents Reagents for clinical coagulation testing covering routine items (PT, APTT, TT, Fibrinogen) and special items (Antithrombin III, von Willebrand Factor Antigen, Protein C, Protein S, Lupus Anticoagulant, FDP, D-Dimer), used for diagnosing and monitoring coagulation disorders, thrombosis, and bleeding diseases on automated coagulation analyzers.
• Blood Grouping Card (Micro-column Gel) Micro-column gel-based blood grouping cards for ABO forward and reverse typing and RhD antigen detection (ABO blood type forward typing and RhD recheck card, ABO reverse typing detection card), used for clinical blood type identification prior to transfusion.
• Gi9000 Fully Automated Chemiluminescence Immunoassay Analyzer High-speed fully automated chemiluminescence immunoassay analyzer with 900 tests/hour throughput and first result time ≤10 min, using enzymatic chemiluminescence detection technology with CV≤3%, on-board reagent loading, and automatic diluent preparation. Designed for clinical immunoassay testing.
• Gi2000 Fully Automated Chemiluminescence Immunoassay Analyzer Bench-top chemiluminescence immunoassay analyzer with 200 tests/hour throughput in a compact 0.43m³ footprint, using enzymatic chemiluminescence technology (CV≤3%), 24h standby, and top-loading reaction cups. Provides comprehensive menu for routine and emergency testing.
• Gi1600 Fully Automated Chemiluminescence Immunoassay Analyzer Compact chemiluminescence analyzer with 120 tests/hour, supporting on-demand reagent and consumable addition. Features enzyme chemiluminescence technology with precision ≤3% across 1 million+ reliability tests, suitable for primary hospitals, outpatient clinics, and specialized laboratories.
• Chemiluminescence Reagent Menu Full menu of chemiluminescence immunoassay reagents covering thyroid function, hormones, inflammation, tumor markers, hypertension, allergy, cardiac, glucose metabolism, anemia, bone metabolism, and rheumatoid factors, compatible with the Gi series analyzers.
• MDC7500 Automated Coagulation Analyzer Self-developed fully automated coagulation analyzer with 20 detection channels, 6 wavelengths (340-800nm), and 155-sample capacity, supporting coagulation, chromogenic substrate, and immunoturbidimetric methods. Provides comprehensive bleeding disorder and thrombosis diagnostics with drug monitoring capabilities.
• MDC3500 Automated Coagulation Analyzer First self-developed fully automated coagulation analyzer offering comprehensive solutions for clinical laboratory bleeding disease detection and thrombosis diagnosis with drug monitoring. Provides high-speed integrated processing and random combinatorial analysis for all assay items.
• MDC7600 Automated Coagulation Analyzer Latest-generation automated coagulation analyzer featuring accurate, high-speed, economical, flexible, and modular design. Supports coagulation, chromogenic, and immunoturbidimetric methods with complete thrombosis and hemostasis testing menu.
• MDC3600 Automated Coagulation Analyzer Automated coagulation analyzer for clinical laboratory coagulation testing applications.
• Coatron Series Automated Coagulation Analyzers Coatron series coagulation analyzers (1800/3000/5000) equipped with LED cold light source. Coatron 1800 offers PT180 speed, Coatron 3000 max 400T/H, Coatron 5000 max PT500 speed. Used for clinical coagulation testing in laboratory settings.
• Gx 3000 Automated Coagulation Analyzer Fully automated coagulation analyzer with advanced detection capabilities for clinical coagulation testing.
• AU240 Automated Biochemistry Analyzer Automated biochemistry analyzer for high-throughput clinical chemistry testing.
• AU200 Automatic Biochemistry Analyzer Automatic biochemistry analyzer for clinical chemistry testing.
• Automated Blood Grouping Analyzer Automated systems for blood grouping including semi-auto blood grouping & screening analyzer, medical incubator, and medical centrifuge, used for micro-column gel blood type detection procedures.
• Titan S Automatic Pathological Staining Analyzer Automated pathological staining analyzer with 36-slide capacity and 42 reagent positions. Supports IHC and other pathology staining applications for clinical pathology laboratories.
• Titan Automatic Pathological Staining Analyzer Automated pathological staining analyzer with 72-slide capacity and 70 reagent positions. Supports IHC and other pathology staining applications.
• Pathology Primary Antibodies (Maixin) Primary antibodies for pathological diagnosis including immunohistochemical (IHC) staining applications, serving the pathology detection segment enabled by the 2020 acquisition of Maixin.
• Liquid Biopsy CTC (Circulating Tumor Cells) Liquid biopsy technology for circulating tumor cell (CTC) detection and analysis, providing oncology diagnostic services. BSBE entered the CTC field through a strategic partnership with Zhongke Natai in 2021.
• GTA6000 Intelligent Laboratory Solution Intelligent laboratory solution integrating BSBE's diagnostic systems (biochemistry, coagulation, chemiluminescence, blood typing, pathology, CTC) into an automated workflow, marketed as an integrated laboratory ecosystem.
• GW Series Fully Automated Coagulation Assembly Line Automated coagulation assembly line integrating sample processing and coagulation testing into a continuous automated workflow, suitable for high-throughput laboratory environments.
• COVID-19 Antigen Self-Testing Kit SARS-CoV-2 antigen rapid self-test kit that obtained CE certification, enabling sale in EU countries and CE-recognized nations for pandemic response.

Quantifiable outcome

• 参考实验室进入JCTLM服务列表，成为全球第16家获此资质的参考测量实验室
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Twelve partnerships are on record, tiered 核心战略合作, 战略合作, 核心战略收购, 战略收购 and 合作伙伴.

• 索灵诊断 (Diasorin)核心战略合作Strategic or Co-development Partner · 3 December 20252025年12月，九强生物与索灵诊断（Diasorin）达成战略合作，共同推动诊断业务发展。双方将基于各自的技术和产品优势开展合作，为中国市场提供更全面的诊断解决方案。
• 中科纳泰战略合作Strategic or Co-development Partner · 23 November 20212021年11月，九强生物与北京中科纳泰科技有限公司签署战略合作协议，共同进军循环肿瘤细胞（CTC）液体活检领域，开展肿瘤诊断服务的全面合作。
• 罗氏诊断 (Roche Diagnostics)核心战略合作GTM or Marketing Partner · 6 November 20212021年11月，九强生物与罗氏诊断宣布再续战略合作新篇章，共同推出全新的生化产品。2016年九强与罗氏中国签署生化试剂战略合作协议。
• 贝克曼库尔特 (Beckman Coulter)战略合作GTM or Marketing Partner · 1 January 20212021年，九强生物与贝克曼库尔特举办生化试剂合作签约仪式，双方在生化试剂领域开展合作。
• 福州迈新生物 (Fuzhou Maixin Bio)核心战略收购Strategic or Co-development Partner · 1 January 20202020年，九强生物与国药投资共同完成对福州迈新生物的收购，迈新的加入意味着九强生物正式进入病理检测领域。迈新生物是中国病理免疫组化领域的龙头企业。
• 美创血凝战略收购Strategic or Co-development Partner · 1 January 20172017年，九强生物收购美创血凝，正式进军血凝市场。
• 雅培 (Abbott)核心战略合作Technology or Integration · 1 January 20162013年与雅培中国签署生化试剂战略合作协议；2016年与雅培进行生化试剂深度合作，开创中国IVD企业技术输出的先河；2021年与雅培签署合作协议进一步深化本土合作；2022年九强生物&雅培Alinity平台第一批合作生化试剂正式上市。
• 迈瑞医疗 (Mindray)合作伙伴Channel Partner/ Reseller/ Distributor迈瑞医疗是全球领先的医疗设备与解决方案供应商，九强生物与其建立合作关系。
• 日立 (Hitachi)合作伙伴Channel Partner/ Reseller/ Distributor日立是来自日本的全球500强综合跨国集团，九强生物与其建立合作关系。
• 科华生物 (KeHua Bioengineering)合作伙伴Channel Partner/ Reseller/ Distributor科华生物是诊断用品专业公司，九强生物与其建立合作关系。
• 威高集团 (Weigao Group)合作伙伴Channel Partner/ Reseller/ Distributor威高集团始建于1988年，以一次性医疗器械和药业为主业，九强生物与其建立合作关系。
• 润达医疗 (Runda Medical)合作伙伴Channel Partner/ Reseller/ Distributor润达医疗是一家立足华东、辐射全国的医学实验室综合服务商，九强生物与其建立合作关系。

Scale indicators4 records

Recent moves11 records

Expansion highlights7 records

Regional players

• KeHua Bioengineering: KeHua Bioengineering is a Chinese specialty IVD and clinical chemistry reagents supplier focused on diagnostic consumables. As a BSBE channel partner, it represents the cohort of mid-sized domestic IVD players competing for chemistry and coagulation reagent share in Chinese hospitals.
• Runda Medical: Runda Medical is a Chinese integrated medical laboratory service and IVD distributor operating across eastern China. Listed as a BSBE channel partner, it provides a useful regional peer for understanding how multi-platform IVD suppliers monetize through integrated lab services and distribution.

Direct peers

• Snibe (Shenzhen New Industries Biomedical Engineering): Snibe is a Chinese chemiluminescence immunoassay specialist whose MAGLUMI series directly competes with BSBE's Gi-series analyzers and reagents in Chinese hospital laboratories, particularly in thyroid, tumor marker, and infectious disease panels.
• Sinocare: Sinocare is a major Chinese IVD and blood-glucose monitoring company that has expanded into biochemistry and chemiluminescence reagents. It competes with BSBE in clinical chemistry and immunoassay reagents for hospital and primary-care customers in China.
• Autobio Diagnostics: Autobio is a leading Chinese IVD company offering immunoassay, microbiology, and clinical chemistry systems with a strong chemiluminescence franchise. It competes head-to-head with BSBE in hospital immunoassay and routine biochemistry tenders across China.
• Mindray: Shenzhen-headquartered Mindray is one of China's largest medical device and IVD players, offering biochemistry, chemiluminescence, hematology, and coagulation analyzers and reagents. It is a direct competitor to BSBE across multiple BSBE platforms and is even listed as a channel/distribution partner in BSBE's data.

Broad incumbents

• Abbott Diagnostics: Abbott is a global IVD incumbent whose Alinity ci-series platform is partnered with BSBE for reagent co-development in China. Abbott is both a partner and competitor across immunoassay and clinical chemistry, especially in high-volume Chinese hospital accounts.
• DiaSorin: DiaSorin is a global specialty IVD company focused on immunoassay and molecular diagnostics. Its December 2025 strategic partnership with BSBE pairs an international specialty IVD player with BSBE's domestic hospital reach, while DiaSorin's LIAISON platform competes with BSBE's Gi-series in select menus.
• Roche Diagnostics: Roche Diagnostics is the global IVD leader with cobas biochemistry and immunoassay systems. Although a strategic partner of BSBE since 2016, Roche remains a formidable competitor in Chinese tier-3 hospitals and shapes pricing benchmarks across all BSBE's core reagent categories.
• Beckman Coulter Diagnostics: Beckman Coulter offers Access immunoassay and DxH hematology systems globally and signed a 2021 biochemistry reagent partnership with BSBE. It competes with BSBE in Chinese hospital immunoassay and is an important reference point for analyzer-reagent bundled sales.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/beijing-strong-biotechnologies-inc.

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beijing Strong Biotechnologies